To Evaluate Long-Term Safety and Efficacy of Pregabalin in the Treatment of Neuropathic Pain After Spinal Cord Injury.

• Status: Completed
• Trial end date: 2006-01-01
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate long-term safety and efficacy of pregabalin in the treatment of neuropathic pain after spinal cord injury.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Pregabalin

Criteria

Inclusion Criteria:

• Must have met the inclusion criteria of the preceding double-blind BID study in central pain following spinal cord injury.

• Must have received study medication under double-blind conditions.

Exclusion Criteria:

• Patients cannot participate if they experienced a serious adverse event during the previous double-blind BID study which was determined to be related to the study medication.